Pharmaceuticals

Radioligand Therapy Market Growth Analysis 2026–2030 Highlighting Innovation And Competitive Landscape

May 4, 2026May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Radioligand Therapy Market Grow Between 2026 And 2030?

The radioligand therapy market has seen considerable growth in recent years. Its size is expected to expand from $6.63 billion in 2025 to $7.32 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.4%. This historical expansion can be attributed to several factors, including the limited availability of radioligands, reliance on conventional cancer therapies, growing awareness of targeted therapy benefits, increasing hospital adoption of nuclear medicine techniques, and regulatory approvals for early rlt drugs.

The radioligand therapy market size is anticipated to experience substantial growth in the coming years. It is projected to expand to $10.72 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.0%. This growth during the forecast period is attributable to the introduction of novel alpha and beta emitters, the expansion of combined emission therapies, integration with precision oncology, an increase in clinical trials for neurological and cardiovascular applications, and greater investment in home care and outpatient rlt services. Prominent trends for the forecast period include the increasing adoption of targeted radioligand therapy in oncology, the broadening of alpha and beta emitter-based therapies, the integration of radioligand therapy with personalized medicine approaches, the expansion of hospital and research institution-based rlt programs, and a heightened focus on minimizing side effects and improving patient outcomes.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27403&type=smp

Which Key Drivers Are Affecting The Radioligand Therapy Market Development?

The escalating incidence of cancer is projected to stimulate growth within the radioligand therapy market. Cancer is defined as a condition involving the unchecked proliferation of abnormal cells that can infiltrate surrounding tissues and disseminate throughout the body. The rise in cancer cases is attributed to sustained exposure to environmental pollutants, which harm DNA, impair cell function, and foster irregular cell development. Radioligand therapy functions by delivering radiation precisely to tumor cells through ligands that bind to specific receptors, thereby minimizing harm to healthy tissues and eradicating cancer cells internally. For instance, in October 2025, the National Health Service (NHS), a UK-based government health agency, reported 354,820 new cancer diagnoses in 2023, equating to an average of 972 per day, which signifies an increase of 8,605 compared to 2022. Consequently, the increasing cancer incidence is driving the growth of the radioligand therapy market.

Which Segment Types Are Examined In The Radioligand Therapy Market Segment Study?

The radioligand therapy market covered in this report is segmented –

1) By Type Of Radioligand: Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions

2) By Molecular Target: Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets

3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral

4) By Application: Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases

5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings

Subsegments:

1) By Alpha Emitters: Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213)

2) By Beta Emitters: Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153)

3) By Auger Emitters: Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201)

4) By Combined Emissions: Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212)

What Trends Are Transforming The Radioligand Therapy Market?

Companies operating in the radioligand therapy market are focusing on developing advanced solutions, such as radioligand therapy facilities, to boost production efficiency and maintain high quality and safety standards in the manufacturing and distribution of targeted cancer treatments. These radioligand therapy facilities are specialized centers designed to manage and deliver radioactive drugs for targeted cancer treatment, utilizing advanced imaging systems and radiation shielding, while ensuring safety through trained personnel and strict protocols. For instance, in January 2024, Novartis AG, a Switzerland-based pharmaceutical company, announced the automation of its new large-scale radioligand therapy (RLT) production plant in Indiana. This plant received Food and Drug Administration (FDA) approval for commercial manufacturing. This 70,000-square-foot facility is the largest and most advanced Novartis site dedicated to RLT, designed for efficient, time-sensitive production, and includes plans for fully automated production lines, enabling substantial supply increases to meet growing patient demand in the US and Canada.

Which Players Are Part Of The Competitive Landscape Of The Radioligand Therapy Market?

Major companies operating in the radioligand therapy market are Novartis AG, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Telix Pharmaceuticals, Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc.

Get The Full Radioligand Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/radioligand-therapy-global-market-report

Where Is The Radioligand Therapy Market Most Concentrated Geographically?

North America was the largest region in the radioligand therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radioligand therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Radioligand Therapy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/radioligand-therapy-global-market-report

Browse Through More Reports Similar to the Global Radioligand Therapy Market 2026, By The Business Research Company

Property Management Service Market Report 2026

https://www.thebusinessresearchcompany.com/report/property-management-service-global-market-report

Real Estate Rental Market Report 2026

https://www.thebusinessresearchcompany.com/report/real-estate-rental-global-market-report

Financial Accounting Advisory Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-accounting-advisory-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795